Objective: The purpose of this study was to evaluate the efficiency, in terms of decreasing overall mortality (primary endpoint), of an immunoglobulin M (IgM)-enriched, polyclonal intravenous immunoglobulin preparation (IVIg) (Pentaglobin; Biotest AG, Dreieich, Germany) in the treatment of a group of patients affected by sepsis after cardiac surgery. A secondary endpoint was to evaluate which subgroup, on the basis of the infectious state when the patient enrolled, could benefit the most from the treatment. Another secondary endpoint was the evaluation of an improvement in the severity score or in other variables such as Glasgow Coma Scale; arterial pressure (systolic, average, and diastolic); heart rate; central venous pressure; cardiac index; respiratory rate; 
S
epsis is a frequent complication in patients admitted to cardiovascular intensive care units, and it is associated with high morbidity and mortality rates. The estimated incidence is about 2%, whereas the mortality rate is about 32%. 1 Despite the evolution of support therapy and the use of new and potent antibiotics, there has been little impact on improvement of the mortality rate from sepsis and, above all, from septic shock since the 1980s. 2 In fact, in the 1980s, the mortality rate from septic shock varied from 40% to 90% according to various authors. 3, 4 About 10 years later, Brun-Buisson et al 5 reported a 56% mortality rate from severe sepsis and septic shock, similar to the 64% found by Knaus et al. 6 Consequently, attempts have been made to lower the mortality rate with new adjuvant therapies that carried out a modulating role on the inflammatory response of the organism to sepsis. In this, immunoglobulins were found to be very effective.
The first studies were performed with antiendotoxin monoclonal antibodies (predominantly against lipopolysaccharide) or anticytokines. Meta-analysis of the studies performed with these preparations did not show a significant decrease in the mortality rate. 7 With the polyclonal immunoglobulin preparations, a significant decrease in the mortality rate was obtained; taken together, the studies taken into consideration by the meta-analysis and by the Cochrane Library collectively show a significant reduction in the mortality rate, both in the analyses on the polyclonal immunoglobulins (n ϭ 492, relative ratio [RR] ϭ 0.64; 95% confidence interval [CI] , 0.51-0.80) and in those on the immunoglobulin M (IgM)-enriched immunoglobulins (RR ϭ 0.48; 95% CI, 0.30-0.76). 7 In the setting of the cardiovascular intensive care unit (ICU), there are studies that verify the efficacy of IgM in the prevention of sepsis 8 and in early treatment with immunoglobulins which improve disease severity and in-hospital survival in high-risk patients after cardiac surgery. 9, 10 The aim of this study was to retrospectively evaluate the efficacy, in terms of decreasing mortality, of the use of IgM-enriched immunoglobulins for sepsis in cardiac surgery. age admitted to the cardiac surgery ICU after different types of surgery were considered eligible ( Table 1 ). The following were considered necessary conditions for inclusion in the study: a hospital stay of more than 11 days, current infection documented by therapy with at least 2 antibiotics in combination, and by clinical signs (such as fever Ͼ38°C or hypothermia Ͻ36°C), laboratory results (positive cultures, leukocytes Ͼ12,000/mm 3 , or leukopenia Ͻ4,000), and clinical examinations (eg, chest radiograph positive for an inflammatory process). The data were collected from the case histories.
Sixty-six patients were enrolled and were divided into 2 homogenous groups: the intravenous immunoglobulin (IVIg) group and the control group (Table 2) . The IVIg group (22 cases) was treated with IVIgs enriched with IgM (Pentaglobin; Biotest AG, Dreieich, Germany), and the control group (44 controls) was treated with standard therapy. The controls enrolled were matched to the cases on the basis of the initial clinical situation (Acute Physiology and Chronic Health Evaluation [APACHE] II score in the first 24 hours equal to the reference case Ϯ 4 points) and age (equal to the reference case Ϯ 10 years).
In addition to antibiotic therapy, the patients in the IVIg group were treated with a preparation of IgM-enriched immunoglobulins at a concentration of 5% (Pentaglobin). The patients received Pentaglobin in the following dosage: 5 mL/kg daily on 3 consecutive days. The evaluation period was 7 days; for the cases, it began with the first day of therapy with IVIg; for the controls, it began at the start of the combined antibiotic therapy after the diagnosis of sepsis. The following were evaluated for every patient on admittance to the study and daily until the seventh day: the severity scores (APACHE II and SOFA), the trend of the indices of inflammation (leukocytes, temperature, cardiac and respiratory rates), the trend of the hemodynamic parameters, the duration of the ICU stay, and the outcome.
The primary endpoint was to evaluate the efficacy, in terms of decreasing mortality, of the IgM-enriched immunoglobulins in the treatment of sepsis. A secondary endpoint was to evaluate which subgroup, on the basis of the stage of sepsis upon enrollment, could benefit more from the treatment. The sepsis stage was defined according to the criteria of the Consensus Conference American College of Chest Physicians/Society of Critical Care Medicine (ACCP/ACCM) 1991 2 (Table 2 ). Another secondary endpoint was the evaluation of improvement in the severity score or in other variables such as Glasgow Coma Scale; arterial pressure (systolic, average, and diastolic); heart rate; central venous pressure; cardiac index; respiratory rate; PaO 2 , F I O 2 , and the ratio of PaO 2 to F I O 2 ; pH, base excess (BE), and bicarbonate; C reactive protein and leukocytes; platelets, prothrombin time, partial thromboplastin time, fibrinogen, and anti-thrombin III; creatinine; and bilirubin.
The comparison of the 2 study groups was carried out using the Student t test for the continuous variables and the chi-square test for the dichotomous variables. The scores (APACHE II and SOFA) were compared by the Student t test both at the beginning of the study and every day until the seventh day. The significance level adopted (p value) was under 5% (Ͻ0.05).
Furthermore, univariate analyses were carried out to identify the potential risk factors for mortality; the factors that were significant were included in a logistic regression model according to a stepwise approach in such a way as to identify the independent variables that explain mortality. Moreover, for analysis of the mortality rate, the actuarial curves of survival according to Kaplan-Meier were used. The statistical analysis was carried out by using the SPSS Windows version 11.0 statistical package (SPSS Inc, Chicago, IL).
RESULTS
In the course of the 2 years of the study, a total of 22 cases were recruited: 4 women and 18 men; to these cases, 44 controls were matched: 21 women and 23 men. Therefore, the number of men was significantly greater than the number of women (p ϭ 0.019). The average age was 62.9 Ϯ 14.2 years in the cases and 68.6 Ϯ 12.3 in the controls (p ϭ 0.09) ( Table 3) .
Emergency surgery was carried out in 22.8% of the cases and in 27.3% of the controls; elective surgery took place in the remaining patients. At the beginning, the 2 groups were homogenous as far as the APACHE II severity score is concerned (IVIg group, average 20.5 Ϯ 5.8; control group, average 21.5 Ϯ 5.4) and SOFA (IVIg group, average 11.6 Ϯ 3.7; control group, average 11.7 Ϯ 3.4). Moreover, there were not any significant differences for the following variables: Glasgow Coma Scale; arterial pressure (systolic, average, and diastolic); heart rate; The systemic inflammatory response to a variety of severe clinical insults, manifested by 2 or more of the following conditions: Temperature Ͼ38°C or Ͻ36°C Heart rate Ͼ90 beats/min Respiratory rate Ͼ20 breaths/min or PaCO 2 Ͻ32 mmHg White blood cell count Ͼ12.000/mm 3 or Ͻ4.000/mm 3 , or Ͼ10% immature (band) form Sepsis: The systemic response to infection, manifested by 2 or more of the following conditions as a result of infection:
Temperature Ͼ38°C or Ͻ36°C Heart rate Ͼ90 beats/min Respiratory rate Ͼ20 breaths/min or PaCO 2 Ͻ32 mmHg White blood cell count Ͼ12.000/mm 3 or Ͻ4.000/mm 3 , or Ͼ10% immature (band) form Severe/Sepsis: Sepsis associated with organ dysfunction, hypoperfusion, or hypotension. Hypoperfusion and perfusion abnormalities may include, but are not limited to, lactic acidosis, oliguria, or an acute alteration in the mental status Septic shock: Sepsis-induced hypotension despite adequate fluid resuscitation along with the presence of abnormalities that may include, but are not limited to, lactic acidosis, oliguria, or an acute alteration in the mental status. Patients who are receiving inotropic or vasopressor agents may not be hypotensive at the time that perfusion abnormalities are measured 441 IgM-ENRICHED IMMUNOGLOBULINS central venous pressure; cardiac index; respiratory rate; PaO 2 , F I O 2 , and the ratio of PaO 2 to F I O 2 ; pH, BE, and bicarbonate; C reactive protein and leukocytes; platelets, prothrombin time, partial thromboplastin time, fibrinogen, and anti-thrombin III; creatinine; and bilirubin.
On the basis of the severity state of sepsis (criteria of the Consensus Conference ACCP/ACCM 1991), 2 there were 8 patients with sepsis (3 cases and 5 controls), 47 with severe sepsis (15 cases and 32 controls), and 11 with septic shock (4 cases and 7 controls), without significant differences between the 2 groups ( Table 3 ). The most frequently encountered diagnosis in both groups was that of pneumonia (in 42 patients, 13 cases and 29 controls); in the remaining 11 patients (5 cases and 6 controls), other diagnoses were encountered (endocarditis, mediastinitis, upper respiratory infection, and urinary infection). The relative frequency distributions of the 2 groups were not significantly different (Table 3 ).
In the patients treated, a drop of the APACHE II score from an average value of 20.5 Ϯ 5.8 to 19.5 Ϯ 8.9 was encountered after 7 days; the controls were unchanged after 7 days (APACHE II of 21.5 Ϯ 5.8 on the day of recruitment v 20.7 Ϯ 7.9 after 7 days). The difference did not reach statistical significance. For the SOFA score, the treated patients had a decrease in average value from 11.6 Ϯ 3.7 to 10.7 Ϯ 4.4, whereas for the controls the decrease was less, from 11.7 Ϯ 3.4 to 11.1 Ϯ 4.1. There were no statistically significant differences in the 2 groups.
Twenty-two patients were monitored using a pulmonary artery catheter; at the beginning of the study, 9 patients in the IVIg group had an average cardiac index of 3 Ϯ 1.3 and 13 patients in the control group had an average cardiac index of 2.4 Ϯ 0.8 L/min/m 2 . After 7 days, there was a significant difference in the average values of the cardiac index favoring the patients in the IVIg group. (The average cardiac index of the patients in the IVIg group was 3.6 Ϯ 1.2 versus 2.6 Ϯ 0.7 L/min/m 2 of the patients in the control group, p ϭ 0.03.) Regarding the remaining continuous variables, there were no significant differences between the 2 groups at the end of 7 days.
Among all the patients (n ϭ 66) examined, 21 patients died (31.8%); no significant differences between groups were observed with respect to overall mortality (5 patients in the IVIG group [22.7%] v 16 in the control group [36.4%]). On univariate analysis, the following variables were correlated with the mortality rate: APACHE II score (p ϭ 0.0045), SOFA score (p ϭ 0.014), PaCO 2 (p ϭ 0.07), respiratory rate (p ϭ 0.04), pH (p ϭ 0.06), and creatinine (p ϭ 0.008) ( Table 4) . On multivariate analysis, the APACHE score was the only variable independently correlated with the total number of deaths (odds ratio [OR] ϭ 1.2, p ϭ 0.008) ( Table 5 ). Pentaglobin did not significantly reduce overall mortality, but the authors observed a In the group with pneumonia (42 patients), the mortality rate was 33%; in this case, there was a difference, although not statistically significant, between the group of the treated cases and that of the controls (23% v 38%, respectively). This was a clear trend to reduced mortality rate with a difference of 15%. In the patients with bacteremia, there was a mortality rate of 44% (0/9) in the control group, and there were no deaths of the 4 cases in the IVIg group. In the other infections (11 patients), there was 1 death among the patients of the control group and 2 deaths among those in the IVIg group (Table 6) .
Analyzing the mortality rate on the basis of the sepsis stages at enrollment in the study, there was 1 in 8 (12.5%) patients with sepsis, 13 of 47 patients (27.7%) with severe sepsis, and 7 of 11 patients (63.6%) with septic shock. The patients with severe sepsis had a mortality rate in the IVIg group significantly lower with respect to the control group: 1 death of the 15 patients treated (6.6%) versus 12 of the 32 controls (37.5%) (p ϭ 0.02) ( Table 7) . Therefore, the authors evaluated other variables seen at the beginning of the study that correlated with the mortality rate in the subgroup of 47 patients with severe sepsis; the deceased patients had an average APACHE II score significantly higher with respect to the survivors (23.9 Ϯ 5.7 v 19.7 Ϯ 4.3, p ϭ 0.01). Moreover, there was a difference for the following variables: platelet count (155,000/mm 3 Ϯ 95,000 v 222,000 Ϯ 118,000; p ϭ 0.07) and creatinine (3.3 mg/dL Ϯ 1.8 v 2.3 Ϯ 1.3; p ϭ 0.05). On the basis of these data, the authors carried out stepwise logistic regression, setting mortality as a dependent variable and the following as independent variables: treatment with IVIg, APACHE II score, diuresis, platelets, creatinine, age, sex, and SOFA score (even if the SOFA score was not significant at the first analysis, it was inserted because it has already been shown to be a predictor of mortality) ( Table 8) .
The model constructed stopped at the second step, having isolated only 2 independent variables capable of explaining the mortality rate in a significant manner: the first variable isolated was the APACHE II score (OR ϭ 1.19, p ϭ 0.02; 95% CI, 1.03-1.37) and, at the second step, the variable treatment with IgM-enriched immunoglobulins (OR ϭ 0.108, p ϭ 0.05; 95% CI, 0.01-1.01) was isolated. Altogether, the model was able to explain 85% of the results (Table 8) .
Furthermore, actuarial curves of survival were used, according to Kaplan-Meier, both for the global sample and for the subgroup with severe sepsis. In the first case, the curve of the cases clearly separates from that of the controls at 25 days. In fact, from this point on, there are no cases of mortality in the IVIg group, unlike that of the controls. Nevertheless, this difference was not significant (Fig 1) . The same analysis carried out for the patients with severe sepsis led to a significant difference (p ϭ 0.04, log-rank test) in favor of the IVIg-treated patients with respect to the controls (Fig 2) .
DISCUSSION
The efficacy of the use of polyclonal immunoglobulins in therapy for sepsis and septic shock has been supported by various trials that were collected in a recent Cochrane Library meta-analysis carried out by Alejandria et al. 7 They showed the efficacy of this therapy in significantly reducing mortality rate (RR ϭ 0.64; 95% CI, 0.51-0.80, in favor of the IVIg-treated patients with respect to the controls). 
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Moreover, in the same meta-analysis, a subgroup of 4 trials was considered in which polyclonal IgM-enriched immunoglobulins (Pentaglobin) were used 11-14 ; in this case, a significant decrease in the mortality rate was also verified, comparable to, if not superior to, that obtained with other preparations that were not enriched (RR ϭ 0.48; 95% CI, 0.30-0.76). It is necessary to emphasize how 2 of these studies were carried out on young patients with neonatal sepsis; nevertheless, the analysis done on the 2 trials carried out on adult patients also demonstrated a significant decrease in the mortality rate (RR ϭ 0.62; 95% CI, 0.49-0.79).
The studies cited and conducted on adult patients were carried out on heterogenous groups of patients hospitalized in general ICUs. In the specific setting of the cardiovascular ICU, there are studies that verify the effectiveness of IVIg in the prophylaxis of sepsis. In the study by Kress et al, 8 the polyclonal IVIg enriched with IgM were used for prophylactic purposes in cardiac surgery patients who were anergic on the basis of a skin test (delayed-type hypersensitivity); they verified a smaller incidence of postoperative infections in immunosuppressed patients who were IVIg treated (5% v 43%) (p ϭ 0.007).
In the present study, the authors chose the APACHE II score and the SOFA score as intermediate outcome factors. Studies performed by Pilz et al 9, 10 explored the use of the APACHE II for monitoring seriousness of the patient undergoing cardiac surgery; these authors managed to show a correlation between this score and the prognosis, identifying a decrease of the APACHE II (7 points within 4 days of entry into the study) as a favorable prognostic factor. In the present cases, the APACHE II score was also significantly higher at entry in the study in the deceased patients. Nevertheless, the APACHE II score and the SOFA score did not show a significant decrease at 7 days in the IVIg-treated patients with respect to the controls. Regarding the SOFA score, only the data of Tugrul et al 15 are available in the literature, and they do not differ from what the authors found. For the APACHE II score, there are only 2 studies in the literature that give contrasting results; Tugrul et al used an IVIg preparation enriched with IgM on a sample of 42 patients (of whom 21 were treated), had results analogous to these, and Schedel et al 13 with a selected sample of 55 patients having gram-negative septic shock, using a simple polyclonal preparation, found a significant decrease in the score of the treated group. Nevertheless, it is necessary to specify exactly how they carried out the measurement of the score for a longer period (14 days) and that the difference, even if it was significant from the 5th day, was accentuated progressively in the following days. The reduction in the score found by those authors was principally caused by an improvement in temperature, leukocyte count, average arterial pressure, and heart rate. In the present study, the differences found in these variables were not significant; nevertheless, the improvement of the cardiac index in the treated patients demonstrates a role of hemodynamics in the positive response to sepsis.
With regard to the mortality rate, the total rate in the present study was 21 of 66 (31.8%). The data from the literature and, in particular, those of the largest epidemiologic studies in the general ICU report a mortality rate that varies from 13% to 56%. 2, 5 The values found are in line with these data and are similar to other data specific to a cardiovascular ICU. 1 On the basis of the sepsis stages at the moment of entry into the study, the authors found a mortality rate of 12.5% in patients with sepsis, 27.7% in patients with severe sepsis, and 63.6% in patients with septic shock. Brun-Buisson et al 5 reported a mortality rate from severe sepsis and septic shock of 56%, similar to the 64% found by Knaus et al. 6 ; the data reported by Bone et al 16 (43.2%) were decisively inferior. The mortality rate from uncomplicated sepsis varies from 13% to 40%. Therefore, these data seem to be similar to the studies that reported a higher mortality rate in regard to the group of patients with septic shock; they are in the middle of the range of the results reported in the literature for the other groups.
In the analysis of the comparison of the mortality rate between the 2 groups, no statistically significant differences were found (5 deaths in the treated group [22.7%] v 16 deaths in the controls [36.4%]). Nevertheless, in the analysis of the mortality rate on the basis of the initial sepsis stages, in the subgroup of patients affected by severe sepsis, the treated patients had a mortality rate decidedly lower with respect to the controls (6.6% v 36.5%), and this was statistically significant (p ϭ 0.037 Fisher exact 2-sided test). This significance was confirmed using a logistic regression analysis in which the treatment with IgM-enriched immunoglobulins had an OR of 0.108.
By comparing the studies by the Cochrane Library metaanalysis, 7 which together show a significant reduction in the mortality rate both in the analysis on the polyclonal IVIgs (n ϭ 492; RR ϭ 0.64; 95% CI, 0.51-0.80) and in those on IVIgs enriched with IgM (RR ϭ 0.48; 95% CI, 0.30-0.76) with the authors' cases in terms of percentages, the results are found to be almost superimposable. In fact, the meta-analysis performed by Alejandria et al 7 reported a mortality rate of 34.5% in the patients treated with polyclonal IVIgs versus 47% in the controls, and 17.9% in the patients treated with preparations enriched with IgM versus 37.4% in the controls. The analysis of the total number of trials reports a mortality rate of 27.9% of the treated patients versus 43.3% of the controls.
To conclude, the authors found that therapy with polyclonal IgM-enriched immunoglobulins was not effective in the overall patient population in reducing the mortality rate of sepsis arising after cardiac surgery; however, in the subgroup of patients affected by severe sepsis it did reduce the mortality rate. The authors believe that the difference in mortality rate between the patients treated and the controls did not reach statistical significance only because of the size of the sample. For calculation with the Fisher exact test, group sizes of 252 patients (two-sided, ␣ϭ0.10, ␤ϭ0.05) would be needed, which is unrealistic in a monocentric study within 2 years. Therefore, the tendency to reduced mortality should be noted. Further studies are needed to confirm this impression.
